

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/085402 A1

(51) International Patent Classification⁷: **A61K 38/00**,
38/16

(21) International Application Number: PCT/US02/12891

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/286,240 24 April 2001 (24.04.2001) US

(71) Applicant: **THE GENERAL HOSPITAL CORPORATION** [US/US]; 32 Fruit Street, Boston, MA 02114 (US).

(72) Inventor: **PODOLSKY, Daniel, K.**; 157 Edmunds Road, Wellesley Hills, MA 02181 (US).

(74) Agent: **CLARK, Paul, T.**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 02/085402 A1

(54) Title: METHODS AND COMPOSITIONS FOR TREATING ORAL AND EOSOPHAGEAL LESIONS

(57) Abstract: The invention features methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.

5 **METHODS AND COMPOSITIONS FOR TREATING ORAL**
 AND ESOPHAGEAL LESIONS

Field of the Invention

 This invention provides methods and compositions for treating lesions of
10 the upper alimentary canal including the oral cavity and esophagus.

Background of the Invention

 Oral mucositis is the destruction of the oral mucosal epithelium which
 results in erythema, ulcerations, and pain in the oral cavity. Mucositis often arises
15 as a complication of antineoplastic therapy such as cancer chemotherapy or
 radiotherapy. The painful ulcerative lesions of mucositis can cause patients to
 restrict their oral intake of food and liquids; as a result, they lose weight and
 suffer from dehydration. Severe mucositis can necessitate the de-escalation or the
 complete interruption of anti-neoplastic therapy. Chemotherapy or radiotherapy
20 can also disrupt mucosal epithelium more distally in the gastrointestinal tract
 including the esophagus, stomach, and small and large intestines, resulting in pain
 and organ dysfunction (i.e., diarrhea).

 The mucositis lesions are also sites of secondary infections, acting as
 portals of entry for endogenous oral microorganisms; a particularly serious
25 concern in patients who are immunocompromised. Mucositis is therefore a
 significant risk factor for chronic debilitating local infections (e.g. yeast
 (*Candida*) infections) as well as life-threatening systemic infection (septicemia).
 Patients with mucositis and neutropenia have a relative risk of septicemia that is
 at least four times greater than that of individuals without mucositis.

30 Aphthous ulcers of the mouth (or aphthous stomatitis) are a common and
 painful problem; approximately 10% of the population suffers from these mouth
 sores at one time or another. The cause of outbreaks of aphthous sores are not

well understood, although they tend to be associated with stress and minor injury to the inside of the mouth. No satisfactory treatments are available, although topical application of steroids provides relief for some patients.

5

Summary of the Invention

This invention features a method for treating a lesion of the upper alimentary canal in a mammal by administering to the mammal a therapeutically effect amount of an intestinal trefoil peptide. Preferably, the mammal is a human.

In preferred embodiments, the intestinal trefoil peptide is spasmolytic polypeptide (SP), pS2, or intestinal trefoil factor (ITF). More preferably, the intestinal trefoil peptide is ITF.

Lesions of the upper alimentary canal such as mucositis, aphthous stomatitis, and gingivitis can be treated by the methods of this invention. Additionally, lesions of the upper alimentary canal that result from antineoplastic therapy (i.e., chemotherapy or radiotherapy), Behcet's Disease, biopsy, surgery, tumor resection, thermal or chemical burns, tooth extraction, trauma from any cause, or lesions caused by microbial (i.e., bacterial, viral, or fungal) infection are also amenable to treatment.

In preferred embodiments, the patient is also administered a second therapeutic agent. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone). Preferably, the second therapeutic agent is administered within 3 days, 1 day, 12 hours, 1 hour, or simultaneously with the intestinal trefoil peptide. The second therapeutic agent can be present in the same pharmaceutical composition as the intestinal trefoil peptide.

The invention also features pharmaceutical compositions suitable for delivering an intestinal trefoil peptide to the upper alimentary canal. Preferably, the pharmaceutical composition is an oral spray, an oral rinse (mouthwash), an ointment, a paste, a cream, a gel, chewing gum, a chewable tablet, a lozenge, or a bioerodable film. In one embodiment, the pharmaceutical compositions use bioerodable microspheres to encapsulate one or more of the therapeutic agents. In preferred embodiments of an oral spray, rinse, ointment, paste, gel, or bioerodable film, a mucoadhesive or viscosity-enhancing agent is present.

In other preferred embodiments, the intestinal trefoil peptide of the pharmaceutical composition is SP, pS2, or ITF. More preferably, the intestinal trefoil peptide is ITF. In other preferred embodiments, the pharmaceutical composition further contains a second therapeutic. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone).

By "intestinal trefoil peptide" is meant all mammalian homologs of human spasmolytic polypeptide (SP; also known as TFF2), human pS2 (also known as TFF1) and human intestinal trefoil factor (ITF; also known as TFF3), and biologically active fragments thereof. Homologs of the trefoil peptides have, preferably, 70% amino acid identity to the human sequence, more preferably 85% identity, most preferably 95%, or even 99% sequence identity. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

The term "fragment" is meant to include polypeptides that are truncations or deletions of SP, pS2 and ITF. Preferably, the fragments have 70% amino acid identity to the corresponding regions of the human polypeptide sequence. More

preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence to which they correspond. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

Preferable fragments contain four cysteine residues in any positions which correspond to the cysteines at positions 25, 35, 45, 50, 51, 62, or 71, of human ITF (Figure 1), or positions 31, 41, 51, 56, 57, 68, and 82 of human pS2 (Figure 2). More preferably, fragments contain five cysteine residues at these positions. Most preferably, six, or even all seven cysteines are present.

Fragments of SP are meant to include truncations or deletions and preferably have 70% sequence identity to the corresponding human SP polypeptide sequence (Figure 3). More preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence. Preferably, active fragments contain at least four cysteine residues which correspond to positions 6, 8, 19, 29, 34, 35, 46, 58, 68, 78, 83, 84, 95, and 104 in the human SP polypeptide. More preferably, fragments contain six cysteines which correspond to these positions. Even more preferable are fragments that contain eight cysteines. Most preferable are fragments that contain cysteines at ten, twelve, or even, all fourteen positions.

It is recognized in the art that one function of the identified cysteine residues is to impart the characteristic three-loop (trefoil) structure to the protein. Accordingly, preferred fragments of ITF and pS2 have a least one loop structure, more preferably, the fragments have two loop structures, and most preferably, they have three loop structures. It is equally well recognized that the native SP polypeptide has a six loop confirmation. Preferable fragments contain at least two of these loop structures, more preferably, four loop structures are conserved, and most preferably, five, or even all six loop structures are present.

By "co-formulated" is meant any single pharmaceutical composition which contains two or more therapeutic or biologically active agents.

By "pharmaceutical preparation" or "pharmaceutical composition" is meant any composition which contains at least one therapeutically or biologically active agent and is suitable for administration to a patient. For the purposes of this invention, pharmaceutical compositions suitable for delivering a therapeutic to the upper alimentary canal include, but are not limited to solutions and suspensions delivered either as an oral spray or rinse, pastes, gels, chewable tablets, sublingual, gingival, or buccal wafers and films, chewing gum, lozenges, and other compositions designed to be retained in the mouth for an extended period of time. Any of these formulations can be prepared by well known and accepted methods of art. See, for example, Remington: The Science and Practice of Pharmacy, 19th edition, (ed. AR Gennaro), Mack Publishing Co., Easton, PA, 1995.

By "microsphere" is meant a bioerodable polymeric pharmaceutical delivery device having a diameter of 5-100 μm and a hollow central core suitable for encapsulation of the therapeutic agent. Typically, the therapeutic agent is encapsulated at the time of microsphere formulation.

By "therapeutically effective amount" is meant an amount sufficient to provide medical benefit. When administering trefoil peptides to a human patient according to the methods described herein, a therapeutically effective amount is usually about 0.1-1000 mg of intestinal trefoil peptide per day. Preferably, the patient receives, 10 mg, 100 mg, 250 mg, or 750 mg of intestinal trefoil peptide each day. The total daily dose can be divided into multiple individual doses.

By "upper alimentary canal" is meant the portion of the digestive system proximal to the cardiac sphincter (cardioesophageal sphincter) of the stomach. Specifically, the upper alimentary canal is meant to include the oral cavity and associated structures (e.g., the tongue, gingival and sublingual tissues, and the hard and soft palates) and the esophagus.

By "biologically active," when referring to an intestinal trefoil peptide, fragment, or homolog is meant any polypeptide that exhibits an activity common to its related, naturally occurring family member, and that the activity is common to the family of naturally occurring intestinal trefoil peptides. An example of a
5 biological activity common to the family of trefoil peptides is the ability to alter gastrointestinal motility in a mammal.

By "isolated DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the given DNA is derived, flank the DNA. Thus, the term "isolated DNA" encompasses, for
10 example, cDNA, cloned genomic DNA, and synthetic DNA.

By "treating" is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The active ingredients of the pharmaceutical composition can treat the primary indication (i.e., epithelial lesion) or secondary symptoms (e.g., concomitant infection, pain, or
15 inflammation).

By "analgesic" is meant an agent which relieves pain by elevating the pain threshold without significantly disturbing the consciousness of the patient.

By "antimicrobial agent" is meant any compound that alters the growth of bacteria or fungi cells, or viruses whereby growth is prevented, stabilized, or
20 inhibited, or wherein the microbes are killed. In other words, the antimicrobial agents can be microbiocidal or microbiostatic.

By "thermal burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to excessive temperature. Thermal burns of the upper alimentary canal are usually caused by ingestion of overly-heated foods and
25 liquids, or inhalation of super-heated air. Thermal burns are meant to include, but are not limited to, burns classified as first degree, second degree, and third degree burns.

By "chemical burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to noxious chemicals. Typically,
30 chemical exposures of the upper alimentary canal are caused by inhalation or

ingestion.

By "antineoplastic therapy" is meant any treatment regimen used to treat cancer. Typical antineoplastic therapies include chemotherapy and radiation therapy.

5

Brief Description of Drawings

Figure 1 is the amino acid sequence of a human intestinal trefoil factor (ITF; Accession No. BAA95531; SEQ ID NO: 1).

Figure 2 is the amino acid sequence of a human pS2 protein (Accession
10 No. NP_003216; SEQ ID NO: 2).

Figure 3 is the amino acid sequence of human spasmolytic polypeptide (SP; Accession No. 1909187A; SEQ ID NO:3).

Figure 4 is a cDNA sequence encoding a human intestinal trefoil factor (SEQ ID NO: 4).

15 Figure 5 is a cDNA sequence encoding a human pS2 protein (SEQ ID NO: 5).

Figure 6 is a cDNA sequence encoding a human spasmolytic polypeptide (SEQ ID NO: 6).

Figure 7 is the nucleotide sequence of a gene encoding human intestinal
20 trefoil factor (locus 10280533:52117-55412; SEQ ID NO: 7).

Figure 8 is the nucleotide sequence of a gene encoding human pS2 protein (locus 10280533:16511-21132; SEQ ID NO: 8).

Figure 9 is the nucleotide sequence of a gene encoding human spasmolytic polypeptide (locus 10280533:957-5208; SEQ ID NO: 9).

25

Detailed Description

The invention provides methods and compositions useful for the treatment of a wide range of lesions of the upper alimentary canal. The intestinal trefoil peptide therapy of this invention is particularly useful for treating epithelial
30 lesions of the oral and esophageal mucosa, tongue, and gingival tissue.

Mammalian trefoil peptides were discovered in 1982. One of the mammalian trefoil peptides, human intestinal trefoil factor (ITF; TFF3), has been characterized extensively, and is described in U.S. Patent Nos. 6,063,755, and 6,221,840, hereby incorporated by reference. The other two known human
5 intestinal trefoil peptides are spasmodic polypeptide (SP; TFF2) and pS2 (TFF1). Trefoil peptides, described extensively in the literature (e.g., Sands *et al.*, *Annu. Rev. Physiol.* 58: 253-273 (1996), hereby incorporated by reference), are expressed in the gastrointestinal tract and have a three-loop structure formed by intrachain disulfide bonds between conserved cysteine residues. These peptides
10 protect the intestinal tract from injury and can be used to treat intestinal tract disorders such as peptic ulcers and inflammatory bowel disease. Homologs of these human peptides have been found in a number of non-human animal species. All members of this protein family, both human and non-human, are referred to herein as trefoil peptides. Human ITF will be referred to most extensively in this
15 application; however, the activity of human ITF is common to each of the mammalian intestinal trefoil peptides.

We have discovered that epithelial lesions of the upper alimentary canal including the oral and esophageal mucosa, tongue, and gingival tissue can be treated by local administration of intestinal trefoil peptides. Thus, trefoil peptide
20 therapy, according to the methods of this invention, can be delivered in any pharmaceutical composition which is useful for delivering therapeutics to the upper alimentary canal.

Pharmaceutical Preparations

Oral Sprays, Rinses, and Emulsions

Spray systems are particularly useful for delivering therapeutics to the upper alimentary canal. Suitable spray delivery systems include both pressurized and non-pressurized (pump actuated) delivery devices. The intestinal trefoil peptide-containing solution, delivered as an oral spray, is preferably an aqueous
30 solution; however, organic and inorganic components, emulsifiers, excipients, and

agents that enhance the organoleptic properties (i.e., flavoring agents or odorants) may be included. Optionally, the solution may contain a preservative that prevents microbial growth (i.e., methyl paraben). Although water itself may make up the entire carrier, typical liquid spray formulations contain a co-solvent, for example, propylene glycol, corn syrup, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients. In general, therefore, the compositions of this invention preferably contain from about 1-95% v/v and, most preferably, about 5-50% v/v, of the co-solvent. When prepared as an spray, patients typically self-administer 1-5 times per day. The spray delivery system is normally designed to deliver 50-100 μ l per actuation, and therapy may require 1-5 actuations per dose. The rheological properties of the spray formulation are optimized to allow shear and atomization for droplet formation. Additionally, the spray delivery device is designed to create a droplet size which promotes retention on mucosal surfaces of the upper alimentary canal and minimize respiratory exposure.

Compositions suitable for oral sprays can also be formulated as an oral rinse or mouthwash. Administration of trefoil peptides using these formulations is typically done by swishing, gargling, or rinsing the oral cavity with the formulation. Optionally, these formulations can be swallowed, providing trefoil peptide therapy to the esophagus, stomach, and/or intestines. This delivery method is particularly useful for treating patients suffering related disorders of the intestinal epithelium. For example, patients receiving antineoplastic chemotherapy, in addition to oral mucositis, frequently develop more distal lesions of the gastrointestinal tract such as lesions of the gastric and intestinal epithelium. It is well known that intestinal trefoil peptides, particularly ITF, are stable at stomach pH. Thus, swallowing an intestinal trefoil peptide-containing solution designed primarily for treating oral mucositis may also benefit lesions of the lower alimentary canal (i.e., stomach and intestines).

In an alternative formulation, the intestinal trefoil peptides and/or other therapeutics can be encapsulated in bioerodable microspheres rather than being dissolved in the aqueous phase of the formulation. A wide variety of microencapsulation drug delivery systems have been developed and many share similar polymeric compositions as used for bioerodable films (described below). Polymers commonly used in the formation of microspheres include, for example, poly- ϵ -caprolactone, poly(ϵ -caprolactone-Co-DL-lactic acid), poly(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and poly(ϵ -caprolactone-Co-glycolic acid) (see, for example, Pitt *et al.*, J. Pharm. Sci., 68:1534, 1979).

Microspheres can be made by procedures well known in the art including spray drying, coacervation, and emulsification (see for example Davis *et al.* Microsphere and Drug Therapy, Elsevier, 1984; Benoit *et al.* Biodegradable Microspheres: Advances in Production Technologies, Chapter 3, Ed. Benita, S, Dekker, New York, 1996; Microencapsulation and Related Drug Processes, Ed. Deasy, Dekker, 1984, New York; U.S. Patent No. 6,365,187). Preferably, the microspheres are bioadhesive or are prepared in formulations containing a bioadhesive excipient.

Other technical features of the intestinal trefoil peptide-containing solutions are easily modified to suit the specific pharmaceutical formulation and the clinical indication being treated. For example, the pH and osmolality of the formulation may be adjusted to confer trefoil peptide stability, while minimizing oral irritancy and sensitivity.

Ointments, Pastes, and Gels

Lesions of the oral and esophageal epithelium caused by trauma are amenable to trefoil peptide therapy delivered as an ointment, paste, or gel. The viscous nature of these types of preparations allows for direct application into the wound site. Optionally, the wound site can be covered with a dressing to retain the trefoil peptide-containing composition, protect the lesion from trauma, and/or absorb exudate. As discussed further below, these preparations are particularly

useful to restore epithelial integrity following traumatic surgical procedures such as, for example, tooth extraction, tissue biopsy, or a tumor resection. Such viscous formulations may also have a local barrier effect thereby reducing irritation and pain.

5

Mucoadhesives

A mucoadhesive excipient can be added to any of the previously described pharmaceutical compositions. The mucoadhesive formulations coat the upper alimentary canal providing protection, inhibiting irritation, and accelerating
10 healing of inflamed or damaged tissue. Mucoadhesive formulations also promote prolonged contact of the intestinal trefoil peptide with the mucosal epithelium. Mucoadhesive formulations suitable for use in pharmaceutical preparations delivered by mouth are well known in the art (e.g., U.S. Patent No. 5,458,879). Particularly useful mucoadhesives are hydrogels composed of about 0.05-20% of
15 a water-soluble polymer such as, for example, poly(ethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(vinyl pyrrolidine), poly(acrylic acid), poly(hydroxy ethyl methacrylate), hydroxyethyl ethyl cellulose, hydroxy ethyl cellulose, chitosan, and mixtures thereof. These polymeric formulations can also contain a dispersant such as sodium carboxymethyl cellulose (0.5-5.0%).

20 Other preferred mucoadhesive excipients for liquid compositions are ones that allow the composition to be administered as a flowable liquid but will cause the composition to gel in the upper alimentary canal, thereby providing a bioadhesive effect which acts to hold the therapeutic agents at the lesion site for an extended period of time. The anionic polysaccharides pectin and gellan are
25 examples of materials which when formulated into a suitable composition will gel in the upper alimentary canal, owing to the presence of cations in the mucosal and salivary fluids. The liquid compositions containing pectin or gellan will typically consist of 0.01-20% w/v of the pectin or gellan in water or an aqueous buffer system.

30

Other useful compositions which promote mucoadhesion and prolonged therapeutic retention in the upper alimentary canal are colloidal dispersions containing 2-50% colloidal particles such as silica or titanium dioxide. Such formulations form as a flowable liquid with low viscosity suitable as a mouthwash or for generating a fine mist. However, the particles interact with glycoprotein, especially mucin, transforming the liquid into a viscous gel, providing effective mucoadhesion (e.g., U.S. Patent Nos. 5,993,846 and 6,319,513).

Bioerodable Film Delivery Devices

The most simple bioerodable devices contain the therapeutic agent(s) incorporated into a solid, usually lipid-containing, film or tablet. The device is formulated to remain solid at room temperature, but melt at body temperature, releasing the incorporated therapeutics. Suitable formulations of this type include, for example, cocoa butter.

Polymeric film devices provide several advantages for therapeutic delivery to the oral cavity. Unlike rinses, pastes, gels, and other flowable compositions, a film device can reside for prolonged periods of time (i.e., hours to days) in the oral cavity and provide sustained release throughout its residency. Typically, the film is partially or completely bioerodable and contains a mucoadhesive layer to fasten the film to the oral mucosa. Film devices, in addition to its use for delivering therapeutics, can also provide protection against mechanical injury or microbial infection of a lesion site. This physical barrier function is particularly advantageous when treating conditions such as mucositis or aphthous stomatitis. Additionally, as discussed further below, a film device can be used to release trefoil peptide therapy directly onto the underlying mucosa, into the lumen of the oral cavity, or a combination of both.

Film devices consist of at least two layers; a mucoadhesive layer suitable for attaching the film to the oral mucosa and a bulk layer which contains the active therapeutic(s). Many suitable mucoadhesives are known in the art and are discussed above. Optionally, one or more therapeutics can also be provided in the

adhesive layer.

The bulk layer of the composite delivery device may be made of one or more bioerodable polymeric materials. Suitable polymers include, for example, starch, gelatin, polyethylene glycol, polypropylene glycol, polyethylene oxide, copolymers of ethylene oxide and propylene oxide, copolymers of polyethylene glycol and polypropylene glycol, polytetramethylene glycol, polyether urethane, hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, alginate, collagen, polylactide, poly(lactide-co-glycolide) (PLGA), calcium polycarbophil, polyethymethacrylate, cellulose acetate, propylene glycol, polyacrylic acid, crosslinked polyacrylic acid, hydroxyethyl methacrylate/methyl methacrylate copolymer, silicon/ethyl cellulose/polyethylene glycol, urethane polyacrylate, polystyrene, polysulfone, polycarbonate, polyorthoesters, polyanhydrides, poly(amino acids), partially and completely hydrolyzed alkylene-vinyl acetate copolymers, polyvinyl chloride, polymers of polyvinyl acetate, polyvinyl alkyl ethers, styrene acrylonitrile copolymers, poly(ethylene terphthalate), polyalkylenes, poly(vinyl imidazole), polyesters and combinations of two or more of these polymers.

A particularly useful bulk layer polymer consists of PLGA and ethyl cellulose. PLGA is bioerodable and can be formulated to degrade over a wide range of conditions and rates. Ethyl cellulose is a water-insoluble polymer that can act as a plasticizer for the PLGA when a film is formed, but will be eroded in a bodily fluid. Due to its water-insolubility, it also has an effect on the degree and rate of swelling of the resultant film.

An optional third layer which is impermeable to the trefoil peptide can also be added to the wafer. Preferably, this barrier layer is also bioerodable. Suitable barrier layer polymers include ethyl cellulose, poly(acrylic acid), or other polyelectrolytes. In one configuration, the barrier layer is placed on the opposite side of the bulk layer relative to the adhesive layer, thereby directing the released therapeutic agent onto the contacted epithelium rather than being diluted in the luminal fluid. This configuration is particularly useful for treating discrete

lesions (i.e., mucositis or aphthous stomatitis) of the tongue, sublingual tissue, or buccal mucosa. In an alternative configuration of the film device, the barrier layer is placed between the bulk layer and the adhesive layer. This configuration directs therapeutic release into the lumen of the oral cavity and is useful for
5 treating more diffuse lesions of the tongue, oral cavity, and esophagus. The configuration is also useful for delivering therapeutics which are cytotoxic when administered at high concentrations because it has the effect of shielding the underlying tissue from direct contact with the therapeutic-containing film.

10 Chewable Tablets, Lozenges, and Confectionaries

Preparing a trefoil peptide-containing composition as a chewable tablet, lozenge, or a confectionary such as chewing gum provides several advantages to traditional drug delivery vehicles. First, prolonged contact and sustained release at the target site (mouth and esophagus) is achieved. Second, such formulations
15 often results in higher patient compliance, especially when administering trefoil peptides to children.

Formulations for chewable tablets are well known and typically contain a base of sugar, starch, or lipid and a flavoring agent. An exemplary formulation for a chewable tablet is provided below.

20 *Chewable ITF Tablet Formulation (per tablet)*

Intestinal trefoil factor – 300 mg
Mannitol – 675 mg
Microcrystalline cellulose – 75mg
Corn starch – 30 mg
25 Calcium stearate – 22 mg
Flavoring Agent (i.e., sodium saccharin or peppermint oil)

The incorporation of therapeutics into chewing gum and other confectionary style formulations is known in the art (e.g., U.S. Patent No.
30 5,858,391).

Therapeutics Agents

Trefoil Peptides

In preferred embodiments, the trefoil peptide is a human trefoil peptide. More preferably, it is human intestinal trefoil factor (ITF), spasmolytic.

5 polypeptide (SP), or pS2. Most preferably, the trefoil peptide is human ITF.

The trefoil peptides are present in the compositions of the invention at a concentration of between 0.1-1000 mg/ml, depending on the nature and condition of the lesion being treated, the anticipated frequency and duration of therapy, and the type of pharmaceutical composition used to deliver the trefoil peptide.

10 Typically, therapy is designed to deliver 0.1-500 mg of trefoil peptide per day to the patient.

Anti-Inflammatory Agents

Any suitable anti-inflammatory agent can be formulated in the
15 compositions of the invention, at concentrations known for these agents. Many of the most useful anti-inflammatory agents also have analgesic and/or antipyretic properties. Anti-inflammatory agents suitable for co-formulation with a trefoil peptide include, for example, acetaminophen, aspirin (acetylsalicylic acid), ibuprofen, phenylbutazone, indomethacin, sulindac, diclofenac, and naproxen.

20

Antimicrobial Agents

Any of the many known microbial agents can be used in the compositions of the invention at concentrations generally used for these agents. Antimicrobial agents include antibacterials, antifungals, antivirals, and other topical antiseptics.

25 Examples of antibacterial agents (antibiotics) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin,
30 streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin,

and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.

Antiviral agents are substances capable of destroying or suppressing the replication of viruses. Examples of anti-viral agents include 1,-D-ribofuranosyl-
5 1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors,
10 attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir.

Antifungal agents include both fungicidal and fungistatic agents such as, for example, amphotericin B, butylparaben, clindamycin, econazole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.

15 Topical antiseptics include agents such as, for example, povidone-iodine and benzalkonium chloride.

Analgesics and Anesthetics

Any of the commonly used topical analgesics can be used in the
20 compositions of the invention. The analgesic is present in an amount such that there is provided to the oral lesion a topical concentration of between one-half and five percent concentration for lidocaine (5-50 mg/ml in 20-40 ml per dose of liquid). Examples of other useful anesthetics include procaine, lidocaine, tetracaine, dibucaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino)
25 ethyl ester HCl, mepivacaine, piperocaine, and dyclonine.

Other analgesics include opioids such as, for example, morphine, codeine, hydrocodone, and oxycodone. Any of these analgesics may also be co-formulated with other compounds having analgesic or anti-inflammatory properties, such as acetaminophen, aspirin, and ibuprofen.

Steroids

Steroids are commonly used to treat lesions of the upper alimentary canal. For example, oral aphthous stomatitis is typically treated using a paste preparation of triamcinolone (0.1%), hydrocortisone, fluticasone, or beclomethasone.

5

Conditions of the Upper Alimentary Canal Treated Using Trefoil Peptides

Mucositis

Mucositis is a common condition of the oral cavity which is characterized by inflammation of the mucous membranes. The condition is frequently caused by antineoplastic therapy, including chemotherapy and local radiation therapy. Symptoms of mucositis include ulcerations, redness, and swelling, and is associated with epithelial cell injury and death. Patients suffering from severe mucositis are susceptible to dehydration and malnutrition because mucositis pain limits dietary intake. In severe cases, mucositis can be so debilitating that patients may require prolonged hospitalization, parenteral nutrition, and narcotic pain medication. Additionally, destruction of the mucosal epithelium increases a patient's susceptibility to local and systemic infection. Disruption of the barrier function permits entry of microorganisms and microbial products normally retained in the gut lumen. Thus, pharmaceutical preparations which reduce the adverse effects associated with chemotherapy will improve the patient's quality of life, compliance with self-medication, and may permit administration of higher chemotherapeutic doses. Typically, mucositis is treated using a trefoil peptide-containing rinse or oral spray which the patient self-administers 1-5 times per day. The aqueous solution preferably contains a mucoadhesive and an anti-inflammatory agent. Other therapeutics, such as an topical analgesic agent (e.g., lidocaine) may also be present. Alternatively, if the lesions are few in number and spatially localized, an intestinal trefoil peptide-containing film device can be placed directly over the lesions.

10

15

20

25

Tooth Extraction

Intestinal trefoil peptide-containing compositions of the invention are used to lessen complications and speed healing of the wound created by the extraction of a tooth. An oral rinse, paste, ointment, or gel, as described above, is applied to the site of extraction immediately following the procedure and then 1-4 times per day, as needed, until epithelial regrowth is complete. Preferably, a topical analgesic is included in the formulation to relieve the temporary discomfort caused by the trauma of extraction. As a prophylactic measure, antibiotic agents may also be included in the formulation.

10

Gingivitis

Gingivitis is most commonly a chronic disease requiring ongoing treatment, in some cases for months or even years. The trefoil peptide-containing compositions of the invention can be employed to treat gingivitis, alone or in conjunction with other treatments, particularly with an anti-microbial agent, and most commonly with an antibacterial agent. An oral intestinal trefoil peptide-containing rinse is swished in the patient's mouth at least once every 2-3 days, but as often as thrice daily, over a 3-4 week period, and the regimen is repeated as needed. Alternatively, the trefoil peptide is formulated into a gel or toothpaste. In severe cases, a viscous gel or ointment having a high intestinal trefoil peptide concentration is applied directly to the wound via a pledget with a stick applicator.

Intestinal trefoil peptide-containing compositions can also be delivered in biodegradable drug delivery systems capable of formation of films applied below the gum line (described in U.S. Patent Nos. 5,945,115 and 5,990,194. A biodegradable polymer, admixed with the intestinal trefoil peptide, is provided where the polymer can be injected in as a free-flowing solution below the gum line using a syringe. The polymer solution then, *in situ*, forms a solid biodegradable implant.

30

Aphthous Stomatitis

At the first indication of an outbreak of aphthous stomatitis (generally, the first twinge of pain), the patient swishes the mouth with an intestinal trefoil peptide-containing rinse, 1-4 times per day until the ulcer heals (generally 5-10 days). An intestinal trefoil peptide-containing gel can also be applied to the ulcer, in the same manner that steroid-containing gels are currently used. In addition, a gel can contain both an intestinal trefoil protein and a steroid known to be effective for aphthous stomatitis treatment. A direct application of more concentrated material can be directly applied to the wound via a pledget with a stick applicator. Alternatively, the lesion can be treated directly by applying a bioerodable film device containing both a trefoil peptide and a steroid (i.e., triamcinolone) directly to the lesion. Any formulation useful for treating aphthous stomatitis can also, optionally, contain a local anesthetic (i.e., lidocaine or benzocaine).

15

Behcet's Disease

Behcet's Disease is a rare, multi-system rheumatic disorder characterized by systemic vasculitis. One of the most frequent symptoms of Behcet's Disease is recurrent oral ulcerations which resemble aphthous lesions. Currently, treatment for Behcet's Disease is palliative, not curative. Thus, the intestinal trefoil peptides can be used to treat lesions of the upper alimentary canal in conjunction with currently available Behcet's Disease therapies including, for example, interferon alpha 2A and 2B, levamisole, cyclosporine, cyclophosphamide, and colchicine.

20

Oral Biopsy and Oral Surgery

In cases in which an oral neoplasm is suspected or known to be malignant, a biopsy or a curative resection is performed using a needle or a scalpel, resulting in an open wound. The surgical area, susceptible to infection and inflammation, is treated by rinsing with a trefoil peptide-containing solution 1-4 times per day.

25

Preferably, an analgesic, an anti-inflammatory, and an antibiotic are included in the formulation. Alternatively, a more concentrated gel, paste, or ointment may be directly applied to the lesion site. For post-operative treatment following resection of a malignancy, a topically active chemotherapeutic can be including in
5 the trefoil peptide-containing composition.

Thermal and Chemical Burns

Trauma to the upper alimentary canal is frequently caused by exposure to excessive heat or noxious chemicals. Thermal burns to the upper alimentary canal
10 are frequently mild in nature (i.e., first or second degree burns), resulting from the ingestion of overheated food or drink. More severe thermal burns of the oral mucosa and upper esophagus can be caused by inhalation of super heated air and are frequently observed in firefighters or victims of house or forest fires.

Chemical exposure can also damage the mucosa of the upper alimentary
15 canal. Mild mucosal irritations and burns are often caused by ingestion of acidic food (i.e., fruits). More severe chemical burns are usually associated with accidental industrial or occupational exposures.

The intestinal trefoil peptide-containing pharmaceutical formulations described herein are useful for treating thermal and chemical burns of the upper
20 alimentary canal. Preferably, viscous liquid or gel formulation containing a mucoadhesive is used to prolong mucosal exposure to the trefoil peptide. Alternatively, a sustained release formulation, such as a bioerodable film, is used. Topical analgesics and antimicrobial agents are the most preferred secondary therapeutics to be co-administered.

25

Production of Intestinal Trefoil Peptides

Intestinal trefoil peptides can be produced by any method known in the art for expression of recombinant proteins. Nucleic acids that encode trefoil peptides (e.g., human intestinal trefoil factor (Figure 4 and 7), human pS2 (Figure 5 and 8),
30 and human spasmodic polypeptide (Figure 6 and 9) or fragments thereof may be

introduced into various cell types or cell-free systems for expression thereby allowing large-scale production, purification, and patient therapy.

Eukaryotic and prokaryotic trefoil peptide expression systems may be generated in which an intestinal trefoil peptide gene sequence is introduced into a plasmid or other vector, which is then used to transform living cells. Constructs in which the intestinal trefoil peptide cDNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Prokaryotic and eukaryotic expression systems allow for the expression and recovery of intestinal trefoil peptide fusion proteins in which the trefoil peptide is covalently linked to a tag molecule which facilitates identification and/or purification. An enzymatic or chemical cleavage site can be engineered between the trefoil peptide and the tag molecule so that the tag can be removed following purification.

Typical expression vectors contain promoters that direct the synthesis of large amounts of mRNA corresponding to the inserted intestinal trefoil peptide nucleic acid in the plasmid-bearing cells. They may also include a eukaryotic or prokaryotic origin of replication sequence allowing for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector-containing cells to be selected for in the presence of otherwise toxic drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this manner the gene product is produced on a continuous basis.

Expression of foreign sequences in bacteria, such as *Escherichia coli*, requires the insertion of an intestinal trefoil peptide nucleic acid sequence into a bacterial expression vector. Such plasmid vectors contain several elements required for the propagation of the plasmid in bacteria, and for expression of the DNA inserted into the plasmid. Propagation of only plasmid-bearing bacteria is

achieved by introducing, into the plasmid, selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs. The plasmid also contains a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene. Such promoters may be (but are
5 not necessarily) inducible promoters that initiate transcription upon induction. The plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector. Mammalian cells can also be used to express a trefoil peptide. Stable or transient cell line clones can be made using intestinal trefoil peptide expression vectors to produce the trefoil peptides in a
10 soluble (truncated and tagged) form. Appropriate cell lines include, for example, COS, HEK293T, CHO, or NIH cell lines.

Once the appropriate expression vectors are constructed, they are introduced into an appropriate host cell by transformation techniques, such as, but not limited to, calcium phosphate transfection, DEAE-dextran transfection,
15 electroporation, microinjection, protoplast fusion, or liposome-mediated transfection. The host cells that are transfected with the vectors of this invention may include (but are not limited to) *E. coli* or other bacteria, yeast, fungi, insect cells (using, for example, baculoviral vectors for expression in SF9 insect cells), or cells derived from mice, humans, or other animals. *In vitro* expression of
20 trefoil peptides, fusions, or polypeptide fragments encoded by cloned DNA may also be used. Those skilled in the art of molecular biology will understand that a wide variety of expression systems and purification systems may be used to produce recombinant trefoil peptides and fragments thereof. Some of these systems are described, for example, in Ausubel *et al.* (Current Protocols in
25 Molecular Biology, John Wiley & Sons, New York, NY 2000, hereby incorporated by reference).

Transgenic plants, plant cells and algae are also particularly useful for generating recombinant intestinal trefoil peptides for use in the methods and compositions of the invention. For example, transgenic tobacco plants or cultured
30 transgenic tobacco plant cells expressing an intestinal trefoil peptide can be

created using techniques known in the art (see, for example, U.S. Patent Nos. 5,202,422 and 6,140,075). Transgenic algae expression systems can also be used to produce recombinant intestinal trefoil peptides (see, for example, Chen et al., Curr. Genet. 39:365-370, 2001).

5 Once a recombinant protein is expressed, it can be isolated from cell lysates using protein purification techniques such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds.,
10 Elsevier, 1980).

Polypeptides of the invention, particularly short intestinal trefoil peptide fragments can also be produced by chemical synthesis using, for example, Merrifield solid phase synthesis, solution phase synthesis, or a combination of both (see, for example, the methods described in Solid Phase Peptide Synthesis,
15 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Optionally, peptide fragments are then be condensed by standard peptide assembly chemistry.

Example 1: Mucositis Treatment for Patients Receiving Antineoplastic Therapy

20 Trefoil peptide therapy is initiated prior to antineoplastic therapy (i.e., chemotherapy or radiation therapy), as a prophylactic to delay or prevent the onset of mucositis. Preferably, the patient begins intestinal trefoil peptide therapy three days prior to the first dose of antineoplastic therapy. During the prophylactic stage, the patient rinses the oral cavity with an intestinal trefoil peptide-containing
25 solution. Alternatively, for convenience, the trefoil peptide is provided as a concentrated oral spray. Preferably, the patient swallows the solution, providing protection for the epithelial cells of the esophagus and lower gastrointestinal tract. Rinsing with and swallowing the intestinal trefoil peptide-containing solution continues at least twice daily until oral or esophageal mucositis is detected.

30

In patients with existing mucositis, epithelial healing is promoted using intestinal trefoil peptide therapy as described above. Palliative therapy is provided using benzocaine (a local anesthetic), and nystatin (an antifungal). The intestinal trefoil peptide can be co-formulated with the benzocaine and nystatin.

5 For example, the patient swishes an oral rinse solution (mouthwash), containing all therapeutic agents, 1-5 times each day. Alternatively, the trefoil peptide can be provided in a concentrated oral spray, with or without benzocaine and the nystatin is administered in an oral rinse.

The oral rinse solutions can either be swallowed or spit out. If swallowed,
10 an antacid may also be included in the formulation. Other useful therapeutics which provide palliative therapy include anti-inflammatories (e.g., ibuprofen) and other anti-microbial agents. Exemplary oral rinses useful for treating chemotherapy-induced mucositis are provided below, but are not intended to be limiting. A skilled physician or pharmacist will immediately recognize
15 appropriate substitutions, additions, and deletions that can be made to these formulations.

Rinse#1: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
 - (ii) kaolin-pectin suspension (Kaopectate®)
 - 20 (iii) viscous lidocaine HCl (2%)
 - (iv) nystatin (oral suspension; 100,000 iu/ml)
 - (v) ITF (2.5 mg/ml)
- preferably swallowed after swishing

25 Rinse#2: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
 - (ii) Maalox® (MgOH & AlOH; 40 mg/ml)
 - (iii) viscous lidocaine HCl (2%)
 - (iv) ITF (2.5 mg/ml)
- 30 preferably swallowed after swishing

Other Embodiments

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent
5 application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without
10 departing from the spirit or scope of the appended claims.

What is claimed is:

CLAIMS

1. A method for treating a lesion of the upper alimentary canal of a mammal comprising administering to said patient a therapeutically effective amount of an intestinal trefoil peptide.
- 5 2. The method of claim 1, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.
3. The method of claim 2, wherein said intestinal trefoil peptide is
10 intestinal trefoil factor.
4. The method of claim 1, wherein said mammal is a human.
5. The method of claim 1, wherein said lesion is mucositis.
- 15 6. The method of claim 1, wherein said lesion is aphthous stomatitis.
7. The method of claim 1, wherein said lesion is caused by antineoplastic therapy.
- 20 8. The method of claim 7, wherein said antineoplastic therapy is radiation therapy.
9. The method of claim 7, wherein said antineoplastic therapy is
25 chemotherapy.
10. The method of claim 1, wherein said lesion is the result of gingivitis.
11. The method of claim 1, wherein said lesion is the result of tooth
30 extraction.

12. The method of claim 1, wherein said lesion is the result of a biopsy procedure or surgical intervention.

5 13. The method of claim 1, wherein said lesion is the result of tumor resection.

14. The method of claim 1, wherein said lesion is caused by thermal or chemical burn.

10

15. The method of claim 1, wherein said lesion is caused by Behcet's Disease.

16. The method of claim 1, wherein said lesion is caused by a bacterial,
15 viral, or fungal infection.

17. The method of claim 1, further comprising administering to said mammal a second therapeutic.

20 18. The method of claim 17, wherein said second therapeutic agent is an anti-inflammatory agent.

19. The method of claim 17, wherein said second therapeutic agent is an antibacterial agent.

25

20. The method of claim 19, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

21. The method of claim 19, wherein said antibacterial agent is povidone-
30 iodine.

22. The method of claim 17, wherein said second therapeutic agent is an anti-fungal agent.

5 23. The method of claim 22, wherein said anti-fungal agent is nystatin or Amphotericin B.

24. The method of claim 17, wherein said second therapeutic agent is an anti-viral agent.

10

25. The method of claim 24, wherein said anti-viral agent is acyclovir.

26. The method of claim 17, wherein said second therapeutic agent is an analgesic.

15

27. The method of claim 26, wherein said analgesic is lidocaine or benzocaine.

28. The method of claim 17, wherein said second therapeutic agent is a
20 steroid.

29. The method of claim 28, wherein said steroid is triamcinolone or hydrocortisone.

25 30. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in the same formulation.

31. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in different formulations.

30

32. The method of claim 31, wherein said trefoil peptide and said second therapeutic are administered within 24 hours of each other.

33. The method of claim 32, wherein said trefoil peptide and said second
5 therapeutic are administered within one hour of each other.

34. A composition suitable for therapeutic delivery to the upper alimentary canal of a mammal, said composition comprising an intestinal trefoil peptide.

10 35. The composition of claim 34, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

36. The composition of claim 35, wherein said intestinal trefoil peptide is intestinal trefoil factor.

15

37. The composition of claim 34, wherein said composition is an oral spray.

38. The composition of claim 34, wherein said composition is an oral
20 rinse.

39. The composition of claim 34, wherein said composition is a bioerodable film.

25 40. The composition of claim 34, wherein said composition comprises microspheres.

41. The composition of claim 37, 38, 39, or 40, wherein said composition further comprises a mucoadhesive agent.

30

42. The composition of claim 34, wherein said composition is a chewing gum, lozenge, or chewable tablet.

43. The composition of claim 34, wherein said composition further
5 comprises a second therapeutic agent.

44. The composition of claim 43, wherein said second therapeutic agent is an anti-inflammatory agent.

10 45. The composition of claim 43, wherein said second therapeutic agent is an antibacterial agent.

46. The composition of claim 45, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

15 47. The composition of claim 45, wherein said antibacterial agent is povidone-iodine.

48. The composition of claim 43, wherein said second therapeutic agent is
20 an anti-fungal agent.

49. The composition of claim 48, wherein said anti-fungal agent is nystatin or Amphotericin B.

25 50. The composition of claim 43, wherein said second therapeutic agent is an anti-viral agent.

51. The composition of claim 50, wherein said anti-viral agent is acyclovir.

30

52. The composition of claim 43, wherein said second therapeutic agent is an analgesic.

53. The composition of claim 52, wherein said analgesic is lidocaine or
5 benzocaine.

54. The composition of claim 43, wherein said second therapeutic agent is a steroid.

10 55. The composition of claim 54, wherein said steroid is triamcinolone or hydrocortisone.

FIGURE 1

1 MLGLVLALLS SSSAEYVGL SANQCAVPAK DRVDCGYPHV
41 TPKECNRGC CFDSRIPGVP WCFKPLQBAE CTF

FIGURE 2

1 MATMENKVIC ALVLVSMLAL GTLAEAQTET CTVAPRERQN
41 CGFPGVTPSQ CANKGCCFDD TVRGVPWCFY PNTIDVPPEE
81 ECEF

FIGURE 3

1 EKPSPCQCSR LSPHNRTNCG FPGITSDQCF DNGCCFDSSV
41 TGVFWCFHPL PKQESDQCVN EVSDRRNCGY PGISPEECAS
81 RKCCFSNFIF EVPWCFFPNS VEDCHY

FIGURE 4

```
1   atgctggggc tggtcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg
61  tctgcaaacc agtgtgccgt gccagccaag gacaggggtgg actgcggcta ccccatgtc
121 aaaaaaagg agtgcaacaa ccggggctgc tgctttgact ccaggatccc tggagtgcct
181 tgggtgtttca agcccctgca ggaagcagaa tgcacettct ga
```

FIGURE 5

```
1   atggccacca tggagaacaa ggtgatctgc gccctgggcc tgggtgccat gctggccctc
61  ggcaccctgg cggaggccca gacagagacg tgtacagtgg cccccgtga aagacagaat
121 tgtgggtttc ctggtgtcac gccctcccag tgtgcaaata agggctgctg ttctgacgac
181 accgttcgtg gggccccctg gtgcttctat cctaatacca tcgacgtccc tccagaagag
241 gagtgtgaat tttag
```

FIGURE 6

```
1   atgggacggc gagacgcca gctcctggca gcgctcctcg tctgggggt atgtgcctg
61  gcggggagtg agaaaccctc cccctgccag tgctccaggc tgagcccca taacaggacg
121 aactgcggct tccctggaat caccagtga cagtgttttg acaatggatg ctgtttcgac
181 tccagtgtca ctgggggtccc ctggtgtttc caccctctcc caaagcaaga gtcggatcag
241 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa
301 tgcgcctctc ggaagtgctg cttctccaac ttcattcttg aagtgcctg gtgcttcttc
361 ccgaagtctg tggaagactg ccattactaa
```

FIGURE 7

(page 1 of 2)

```
1   atgctggggc tggctcctggc cttgctgtcc tccagctctg ctgaggagta cgtggggcctg
61  tgtgagtact gccctgactg ccccggtggc aggggtggcg tgaagggag ggatccagga
121 taagggggga ttctgcattc atttaataat ggccacctgt cacatataca ctttttcctg
181 cgctagccct ttgaagtggg tctttattgt ccccathttca cagacaagga aaccgagggt
241 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgttga aatcagggtt
301 tgagcctgag cccatcccct atgaccccat agccatcttt gctggagatt tctaaattac
361 aatataggctc tttatgcatt gttccacatt tacaaagaaa aaggaaagat gcaggagaaa
421 aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcattta gccattgcat
481 agcaaccctg ccatggggtg tggtgtctcc attaacccaa gtttgaagga atgagggtcat
541 ggcttttatc tgggtgtctt ctgagcaggg tcaaaggcag tggttcccga acttgacgac
601 cattagaatc acctggagag ctttaaaaat cctaattgctt ggggcacacc agttacatca
661 gggcatctcc aggcaagatc caggcctcag ctgttttgtt ttgagatagc cttgctttgt
721 cactcactgc tggagtgcag tggcacatc tcagctcact gcaacctccg cctcctgggt
781 tcaagcaatt cttgtgcctc ggcttcaagt agctgggatt acaggcatgc accaccatgc
841 ccagctaatt ttttggtatt ttagtagaga tggagtttcg ctatgttggc caagctgggtc
901 tcaaactcct ggctcaagt gatcctcctg ccttggcctc ccaaagtget ggaattacag
961 gtgtaagcca ccatgcccag ccaacgtcag tcatttttaa agctctgcag ctgattccag
1021 tgtgagcgaa gtttgatgc caggaggata agcaattacg gactgggagc aagagaaggg
1081 aatgtaagac actgcacgtg attgccattt tcctaaggaa atactcagtt cgttaatgaa
1141 acgcagtga cttctgctgc acatacagac atagaggctt gcctgaaaca tgaaaatatt
1201 ggggactgaa ggatgtcccg ggagggtggg acatgctcaa caattcagga aggggagatg
1261 cagaaaaaag tgaaaagcag gcagcatgcg ttgcaatgat ctctatggcg tgtgctctc
1321 ctgtcacggt tttcatttaa aacaaagggg caagggtttg ttggtcaaac aatgaaggg
1381 aactttgttt ctgggttcaa gggaccccag attccccagg ggttctgcc agctggaagg
1441 taccagggtc cgtatgtgac ttcccagaaa ggtgataaga gcgtgccaag gagaaaagaa
1501 cttaggcaaa tggccagagt ccccagctg agcatttaac agactgcctc tctttaaata
1561 ttcacaggga aagtgcattc tcctaagggc gaggggttca gcagtgggtg aactcggcgg
1621 ggtggggcgg agcgggagga tgcaaaactg caaagtgaag caaacacact caccgcagcc
1681 cagcaagggc tctggcagct gacagggtt tgtctgggac agctgcaaac cagtgtgccg
1741 tgccagccaa ggacagggtg gactgcccgt acccccattg caccccaag gagtgcaca
1801 accggggctg ctgctttgac tccaggatcc ctggagtgc ttggtgtttc aagccctgc
1861 aggaagcagg taaggcccca gtggcatcgt ggtctgggac cagcccata aggcagggg
1921 tctcagggac tccctgtcct ttctgggctg gagatggagg cacaaggacc ccaggaagcc
1981 acacacacac acctgttcca aggcctcaga gcagaggctt cacacttagg gcagccatgg
2041 ccaggggctg tctctttctg tcccccttat gtaaaacata aaagcaattg tttcaaaaag
2101 gtgttcaaaa tgatggcatc gcatagaggg aactgattta gtaactattc ttgagagaag
2161 tggaacgca taggtgtgga aagccgggac gacttttggg ctgtttttgc aaatcggccc
2221 ccagagtct tgtcatttgt ggcaccccct acacagacgg caggcgggtc cagccctaga
2281 cgtcaggcct cgggtgccca cccacctcc cccactctgc ccccacaag ggtcatctcc
2341 tctccctctc tctgccgtgg tggagggcag gtgcagggca accaccctgg gggttccctc
2401 cccaggggag gagagcctgc gtgctgtgcg ggtaacagat ggccctgcac acgggtttgc
2461 caccctggct ccaccaggct tagctgcccc acatcgtggg tggggcgatt ggctataagc
2521 catctgccat gtccaagtgc cagctcagcc cccacgaagg ccgcacctgc gtgaggtacc
2581 ttcctggaac cagcatccag aggggcctct cttgcccttt gtcctagggt gaaatcgagg
2641 aggctgagtc ctgctggccc cggctccctg atcaatgatg ggccctgcc cagggcctcc
```

FIGURE 7

(page 2 of 2)

```
2701 cttcacccctc cccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg
2761 agagagaggg gtctggctac tgtccactgc cggtcctggt ccttcagctc cactggaact
2821 acactctcct ctgagtgcc gccatggccc tgccaaggcc catctcgctt gttatctgcc
2881 tgatccctgg gtcccactat cttgcttagc aacccgaggt gggaatcttg gctattcccc
2941 catgtgggtg ggactcaaca ctcccgggtg actctgggga ggaggcagca ctaggtgctg
3001 gccttggagc ctgccctgac cttgggaagc tgggcagcgt ggggtggagag agactgctca
3061 cacaagcctt tgctctgttt gcagaatgca ccttctgagg cacctccagc tgcccccggc
3121 cgggggatgc gaggctcgga gcacccttgc ccggctgtga ttgctgccag gcactgttca
3181 tctcagcttt tctgtccctt tgctccgggc aagcgcttct gctgaaagtt catatctgga
3241 gcctgatgtc ttaacgaata aagggtccat gctccaccg
```


FIGURE 8

(page 1 of 2)

```
1  ccctgggggtg  cagctgagct  agacatggga  cggcgagacg  cccagctcct  ggcagcgctc
61  ctctgctctgg  ggctatgtgc  cctggcgggg  agtgagaaac  cctgtaagtg  aaggagaggg
121 tcttttttatg  tgctttcttt  atttctctta  aagaaaaaaa  aaaagcacia  ccataaatta
181 acttgagagg  gggaatggct  ataaaggcat  ctggcaatgt  gtgtgtttca  catgggattt
241 gccactgctc  aggaggggtg  ctccaagaag  ggctccctc  ctagggaag  gctgagtac
301 ggcaggtgtc  agcggggccc  gtgtcgggcc  aggagggcat  tcccaccaag  ggtccttgga
361 gtcccagagc  actcacctct  cgctcgatc  ttggccttg  gtccatctgt  tcacctcct
421 ctaggaggg  tttgtttttg  tttttttccg  agacaggatc  tggctttg  gccaggcag
481 gagtgcagt  gtgtgatctt  ggctcactgc  aacctctgcc  tcccaggctc  aagtatcct
541 cccacctcag  ccgcctgagt  agctgaaacc  acagtgtgtg  accatcatgc  ccggccaatt
601 tttttttttg  tattgtttgt  agagatgggg  tttcgacatg  ttgccagga  tggcttgaa
661 ctctgagct  caagcaatct  gcccgcctcg  gcttcctaaa  gtgtgggat  tataggtag
721 agccaccatg  cctggctttt  tttttttttt  ccttttaaac  taatataaca  atttcagcaa
781 agccctatcg  gcttctcagg  aggaaccgc  attgcttaa  tatgggcaag  ataagacttt
841 gtgtttctct  atgtggcaac  aagacagtag  aggcattccc  tagaacctct  gagagaagga
901 gcagttagct  ctgggggtacc  aggggtgggg  cgactgaggg  tctttccaca  gccccctgcc
961 agtgctccag  gctgagcccc  cataacagga  cgaactgcgg  cttccctgga  atcaccagt
1021 accagtgttt  tgacaatgga  tgctgtttcg  actccagtgt  cactggggtc  ccctggtgtt
1081 tccacccct  cccaaagcaa  ggtaatcttc  cagggaatct  tccctggcca  gcagctggca
1141 acccaggacc  cagcttcaca  ggcgagccc  agagcagggg  ccggaggagg  cccagtgtct
1201 agtctagggt  tagcctgggt  gggtagtct  cgagctagcc  ccggttggt  agtctggggc
1261 tagcccaggt  tggtagtct  agagctagcc  cagggttggt  agtctggggc  tagcccaggt
1321 tggtagtct  ggggctagcc  cagggttggt  agtttgagc  tagcgcagg  tggtagtct  ggggtagta
1381 aaggctagcc  gttagcctgg  agctagccca  ggttggttag  tctagggcta  gcgtaggctg
1441 gccaggttg  gttagcctgg  ggctagccca  ggttggttag  tctggagcta  gccaggttg  gttagtctgg
1501 gttagtctgg  ggctagccca  ggctagccca  ggttggttag  tctggagcta  gccaggttg  gttagtctgg
1561 ggctagtagc  ccaggttggt  tagtctgggg  ctagccagg  ttggttagtc  tagggctagt  tagggctagt
1621 gtaggctagt  tagtctagg  ctagccagg  ttagttagt  tggagctagc  acaggtgat  ggtagtcta
1681 tagtctgggg  ctagtagcct  aggttggtta  gtctggagct  agcccaagt  ggtagtcta
1741 gggctagcat  aggttggtta  gtctggggct  agtagcctag  gttgttagt  ctggagctag
1801 cccaggttg  ttagtctagg  gctagcgtag  gctggtagt  ctagggctag  cccaggttg  cccaggttg
1861 ttaatcgag  ctagccagg  ttggttagtc  tggagctagc  ccaggttggt  tagtctgagg  tagtctgagg
1921 ctagtagccc  aggttggtta  gtctggggct  agccaggtt  tgtagtctg  gagtagccc  gagtagccc
1981 aggttggtta  gtctggagct  agccaggtt  ggttagtctg  ggactagcct  ggactgctag  ggactgctag
2041 tctagaggt  gcctagagga  ctgctagtct  agaggtagtc  tagggctagc  ccaggttggt  ccaggttggt
2101 tagtctgggg  ctagcccatg  ttggttagtc  ttagactagc  ctggactgct  agtctagagg  agtctagagg
2161 tagcccaggt  tgttttagtct  ggtactagcc  tggactggt  gtctagaggt  agccaggtt  agccaggtt
2221 ggttaggtg  gttagtctgg  gactagtctg  gactgttagt  ctagaggtag  cccaggttg  cccaggttg
2281 ttagtctggg  actagcctgg  actgtagtc  tagaggtagc  ccagattggt  tagtctggga  tagtctggga
2341 ctagtctgga  ctgctagtct  agaggtagcc  cagggttggt  agcctggggc  cagcctggac  cagcctggac
2401 tgtagtcta  gaggttaacc  aggtcagcca  acagtgagat  gaaaatttcc  cacctaccct  cacctaccct
2461 gtttctacac  tgtagttct  ttcaacagac  atgtgtgtgt  ggagccatca  gtttacttt  gtttacttt
2521 agttgagaaa  aaaatatata  tatatatagt  aggtctctc  tagtttttga  agtgtgactt  agtgtgactt
2581 ctgaagaagc  ttccatgggg  aaatgaaggt  atttaataag  acagcagtaa  cataagggct  cataagggct
2641 gacagccctc  aaatgttagg  gaaggaagtg  aagccttcta  gggttctttg  ggagttagtt  ggagttagtt
```

FIGURE 8

(page 2 of 2)

```
2701 ttatgttagt gcacgggatc aggaccaag ttgtaacgcc gacgagtgct caaaggaagg
2761 ttgtgtgtgt gtcgtgcacc tgtgtgcgtg gaaccaggca cgtcctctgg agaaggagga
2821 ttcatcccca agattgttgc tgggaggett gctgggcccc gcagggaaac caggcagatg
2881 gtggattgtt cacgagcgcc cactgaatgg cagtgtcttt gggaatcaat accatgtcca
2941 aacgctttcc atcttaccaa ggtgccaca aaccttttct catcttggcc cgggggacca
3001 cccattttac tgagaacact gagtcccag aggcaaatg atttcccaa ggcgggggac
3061 tccagagctt ctgactgtga ccaccccaca tgggccccac cttecgagg gacaggccag
3121 ccaagcgctg ctggggccga cacttcaca gtccccggg gaggcggtcc caggggccga
3181 cacttcaca gtccccggg gaggcggtcc cgggggatgc tgccccagg agcacctcat
3241 gatccacgga ggctgcaaat cagcgctgct ctacagagg gaaggggtgg agctttccag
3301 ggcacagcag gcctgactgg gtctcggtgc tgtcctgtc ccatggcaga gtcggatcag
3361 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa
3421 tgcgctctc ggaagtgtg cttctccaac ttcattttg aagtgccctg gtgcttcttc
3481 ccgaagtctg tggaaggtaa cgtcgctgtg ggactctctg tctggttccc ggacaccatg
3541 attcctctc cgtccgtaga ggtggggtgc agggagggga gctgcctcgc agcctcagt
3601 ccacgaggc cagggccctt gcctcctatg ggattctgaa ggcaattcca gaattgtctt
3661 ggcaaagaca gcgtcttttc aataagttta tagcctccag cattgccact gcgtcatctg
3721 tgatggctct agaaacagcg gctcatccct gttgcctccc cagggtgttg aacgttcaga
3781 ggcgttgctt gttttattgc aagcccatct gcatttgagg gctactgagt gtcttgact
3841 gtgctgggta ccagagaggg cccaactcaa gcagacctgg ccccttctcc cgtggcttcc
3901 ccgttctccc ccacatgacc ccgaatgaca aacctcatcc acaacgtcct gctccgggca
3961 gtcccgagg ggtcccgcg gcagaggtga acgggtccac ttctcccacc cgttagtga
4021 tagtgtgttc ctgactcgga gtgtggcgag gtaaaaaaag accaagcaga tccaggaaaa
4081 tggggaaaga gctactggcc cttgaaggat gccttttctt ttccttttgt taggatatca
4141 aagcactcca aagagcgaaa tatttcattg tcaggatttt ccgagtgatt tttttatgt
4201 gacctaaagg tccacctaga aaatgttcac ttgtctgggg agaatgcgcc ccacagagga
4261 aactctggcc tggggtggga agatttggtc cttttacacc ccctcccgg gaaaggagct
4321 cttcttcag taggaagctc ctgggcaaag tgatgcacgc ccacccagc ttgcagcct
4381 aggcactccc atttctgggg ttcccttacc aaccatcttg catttaaact tctagactgc
4441 cattactaag agaggctggg tccagaggat gcactctggc caccgggtgt tccgaaacca
4501 aagaagaaac ttcgccttat cagcttcata cttcatgaaa tctggggtt tcttaaccat
4561 cttttcctca ttttcaatgg tttaacatat aatttcttta aataaaacc ttaaatctg
4621 ct
```

FIGURE 9

(page 1 of 2)

```
1  atccctgact  cggggtcgcc  tttggagcag  agaggaggca  atggccacca  tggagaacaa
61  ggtgatctgc  gccctgggtcc  tgggtgtccat  gctggccctc  ggcaccctgg  ccgaggccca
121  gacaggtaag  gcgtgcttct  tcctgctctg  tggggccaca  gccagctctg  gcagcctccg
181  ccaggagcca  ctgttttaca  tacatatatt  tgagcacctg  ttttgtgcca  ggtgctgttc
241  tagggccctta  aaagtatatc  caatttacag  gatcggcaaa  agcagggtga  gagtaactca
301  ggggtggcagg  gcccccgagg  accttcgaga  agtgcgacga  ggagggggct  gccttcagtc
361  ggggctgttt  tcctgtgtta  ggaagactat  acaatcctcc  caagtgtcat  gtttcaaaga
421  ggaagtgttg  gcgtggggtc  tcagaatagt  gcttttgact  gttcatgcca  acatctcccc
481  cagggggcaga  ccctcccaag  gcccatccag  ataggcccaa  atgccggtcc  cagtgtggc
541  cacctgggag  accctctccc  acaggccccg  atgcccgtcc  cagtgtggc  caactgggag
601  accctctcct  acaggttcct  gggctcccc  gggatccatg  ctctgggagt  caaagccacc
661  tctctcatga  gtgcgtggct  ggcaacccat  attccctgg  gttgtcaagt  ggatcgggtg
721  ccctgggtcc  ttctagggag  tggaggagga  ggccattctt  gcttccttgg  gaagtgtttg
781  catctcaact  cctttacctg  cagaatggat  caacggtctg  ccctagggct  gtcaggaaat
841  gctgtgtggc  agcatctgag  acttgcaact  tgccagctgt  ggggagctga  ataacttatt
901  tgccggttatt  aggtacagtt  tcaaggtggg  ggcaggagaa  agggctttct  acgtttccaa
961  agcaaggggt  tccagagagg  cctgaagagg  gagcgcccag  tgggtgctgt  cgtgccccca
1021  ctgccctcca  gccacctctt  gatctctgct  gtggggtacc  gggcctgagg  ggtgggcttg
1081  ggcagcgtag  aagagcagcc  agcattgggc  tgcagtggga  agaccccaa  gcccatggca
1141  gggagcgggg  gagctttgga  acccgagaga  ggaagtggcc  tcggtgtaca  gaacgaactg
1201  ggtgggtccc  cgtgctggcc  acccccaggc  ccatctgcct  gcgcccttgc  cccacccca
1261  gccccagct  ctgccccctg  tgctgtggga  tcacagaggc  cgtggcaaac  tccccctccc
1321  accccacaca  ccctctggct  caaggtcag  agcgtctttg  cgggtcactc  aggtccatga
1381  tcctgttaca  actgaaatct  agaaaattgt  gattacagtt  tagtgcatc  gtgtgtggaa
1441  accatttcca  tttatttcca  tcatgcgaca  aagacaaagc  ggggtgggcaa  gacagagtct
1501  gccggaggca  gagcaccggg  gctggaaatc  ttctccctg  aggaggaaac  cccccgacc
1561  cccaggatga  tgatccctcc  tcaccacggg  gcctctcttg  acccccacag  tgtcccgggg
1621  gtgggcgatg  atcaccttca  cgtcgcgatg  gatccagacc  ccaggagggc  aaggttccca
1681  tggaagctgc  tgggcagcgg  gagctgaaca  cggatccttc  ccagcaagcc  aggaacactt
1741  tctccaaaga  catctcgagg  cagtccttga  tagcaaagca  gacaagagaa  cagccccctc
1801  cggcctcccc  tggggcgccc  tcacctgagc  cagtgtggcc  agactgagtt  cctccccctc
1861  tatgccccaa  ggcagggaca  gggaccggag  ggtgctctgg  gctcctctt  cccccctgc
1921  tgcaggctgt  caaccaccag  atcctaatag  gttgctttct  gagacctttg  attccgagg
1981  gctcagagcc  tgaagctctg  gtgttagaac  ctcttgcata  agatcctgag  gcagccccc
2041  gccagcccca  tctgtccacg  tgtcttcttc  ctctagatcc  ctttctctac  tgccctgctt
2101  caagctgttt  cacagcttgt  accctctgtc  ggctcctcct  agaccacccc  acccggtcct
2161  ctcaccttac  ctgcaatggg  tttccacctc  ctgaacacac  ctgggtctct  ggaatggcct
2221  ttgcccatgc  ggctccatct  tcacctgggt  aacctcctcc  tgcaggaggc  cccctgctt
2281  tgttcaacct  gcttgtcatt  ggctctctcc  gggagtggcc  taccctgtg  gttaccctgg
2341  gcaccctggg  acgatggcct  tgcgttgtct  cgcacatgtt  cttgccttcc  tccctccatc
2401  gatccttaga  ctcttttttt  tttttttttg  agatggagtc  ttgctctgtc  actcaggctg
2461  gagtgcaatg  gtgcgatctt  ggctcaactc  aacctctgcc  tcctgggttc  aagtgtattc
2521  cctgcctcag  cctcccaagt  agctgggatt  acagacgtgt  gccacaatgc  ccgcctaatt
2581  ttttgtattt  ttagtagaga  tggggcttca  ccattttggg  caggctgggt  ttgaactcct
2641  gacctcaagt  gattcacctc  cttcagcctc  ccaaagtgt  gggattacag  gcatgagcct
2701  gggcccagat  atttagactc  ttattaatga  cttctctggg  ttttaattct  gggctctctc
```

FIGURE 9

(page 2 of 2)

```
2761 cacctggcac agtgccctggc ttttgccatg ctagctocca cttctcatgc acacaaatgg
2821 tgctcagtaa atatttatgt attgagtaaa atttaataat catttggtga aattaaaaag
2881 tgaataaata agttacctag aaagatgcaa agtccacaaa cctggggcac cttgcatttt
2941 ccctgagcgt aatgtttgca catcaggatg tgaggaccac gtctccctct catgtcctga
3001 ggggtttata tccgcctcac tggcacgttg ctgatgtcat tggagaagga agctggatgg
3061 gtgtgtgcat gataacatca aggaattcag cccacaactt actttgcttc ttacctgtgc
3121 actttcagag acgtgtacag tggccccccg tgaaagacag aattgtggtt ttcctggtgt
3181 cacgccctcc cagtgtgcaa ataagggctg ctgtttcgac gacaccgttc gtgggggtccc
3241 ctgggtgcttc tatcctaata ccatcgacgt ccctccagaa ggtatggcct ttttatacga
3301 tgggttctga agatttagaa ttagttagaa aagtcattta agactacaga ggctctgatc
3361 agcatcacca gctatgcctt tacacagagt cacggccgcc agtggtggtg caatggggta
3421 gcctgagtca ggctgcattc aggtccagga atagaaaggc agggctaagg gacttgggaa
3481 gaaacctgat ttcccccccg cttctcttca catctctaac caaaagcctg ggaagagcca
3541 ctggttggtaa cgctttctag cttgcctagg atagaggggg aaggcatgac gaaatctgaa
3601 gacatttcat gtattctttt tttttttttt tttttgaaat ggagtctcgc tccgttgccc
3661 ctgagctgga gtgcaatggt gcgatcttgg ctcaactgcaa tctctgcctc ctgagttcaa
3721 cctcagcttc ctagtagctg agattacagg tgtgtgccac tacgcccagc taaatttttt
3781 ttgtattttt agtatagacg gggtttcacc atgttggccg gaccggtcct gaactcttga
3841 cctcaggtga tctgcccgcc tcagcctccc agagagctgg gattacaggc gtgagccacc
3901 gtgcccggct gacagttcat gttttctaaa gaatgtgcct atggatactt taaagtaaaa
3961 actctgtaat tgtttaaatg tgaaagaaaa tgtttatcct cactaaagca tctctttctc
4021 cctccccctc acccctgtag aggagtgtga attttagaca cttctgcagg gatctgcctg
4081 catcctgacg cggtgccgtc cccagcacgg tgattagtcc cagagctcgg ctgccacctc
4141 caccggacac ctcagacacg cttctgcagc tgtgcctcgg ctcacaacac agattgactg
4201 ctctgacttt gactactcaa aattggccta aaaattaaaa gagatcgata tt
```

SEQUENCE LISTING

<110> The General Hospital Corporation

<120> Methods and Compositions for Treating
Oral and Esophageal Lesions

<130> 50206/002WO2

<150> US 60/286,240

<151> 2001-04-24

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapien

<400> 1

```

Met Leu Gly Leu Val Leu Ala Leu Leu Ser Ser Ser Ser Ala Glu Glu
 1           5           10           15
Tyr Val Gly Leu Ser Ala Asn Gln Cys Ala Val Pro Ala Lys Asp Arg
          20           25           30
Val Asp Cys Gly Tyr Pro His Val Thr Pro Lys Glu Cys Asn Asn Arg
          35           40           45
Gly Cys Cys Phe Asp Ser Arg Ile Pro Gly Val Pro Trp Cys Phe Lys
          50           55           60
Pro Leu Gln Glu Ala Glu Cys Thr Phe
65           70

```

<210> 2

<211> 84

<212> PRT

<213> Homo sapien

<400> 2

```

Met Ala Thr Met Glu Asn Lys Val Ile Cys Ala Leu Val Leu Val Ser
 1           5           10           15
Met Leu Ala Leu Gly Thr Leu Ala Glu Ala Gln Thr Glu Thr Cys Thr
          20           25           30
Val Ala Pro Arg Glu Arg Gln Asn Cys Gly Phe Pro Gly Val Thr Pro
          35           40           45
Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe Asp Asp Thr Val Arg Gly
          50           55           60
Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile Asp Val Pro Pro Glu Glu
65           70           75           80
Glu Cys Glu Phe

```

<210> 3

<211> 106

<212> PRT

<213> Homo sapien

<400> 3

Glu	Lys	Pro	Ser	Pro	Cys	Gln	Cys	Ser	Arg	Leu	Ser	Pro	His	Asn	Arg
1				5					10					15	
Thr	Asn	Cys	Gly	Phe	Pro	Gly	Ile	Thr	Ser	Asp	Gln	Cys	Phe	Asp	Asn
			20					25					30		
Gly	Cys	Cys	Phe	Asp	Ser	Ser	Val	Thr	Gly	Val	Pro	Trp	Cys	Phe	His
		35					40					45			
Pro	Leu	Pro	Lys	Gln	Glu	Ser	Asp	Gln	Cys	Val	Met	Glu	Val	Ser	Asp
	50					55					60				
Arg	Arg	Asn	Cys	Gly	Tyr	Pro	Gly	Ile	Ser	Pro	Glu	Glu	Cys	Ala	Ser
65					70					75				80	
Arg	Lys	Cys	Cys	Phe	Ser	Asn	Phe	Ile	Phe	Glu	Val	Pro	Trp	Cys	Phe
				85					90					95	
Phe	Pro	Asn	Ser	Val	Glu	Asp	Cys	His	Tyr						
			100					105							

<210> 4

<211> 222

<212> DNA

<213> Homo sapien

<400> 4

atgctggggc	tggtcctggc	cttgctgtcc	tccagctctg	ctgaggagta	cgtgggcctg	60
tctgcaaacc	agtgtgccgt	gccagccaag	gacagggtag	actgcggcta	ccccatgtc	120
acccccaaag	agtgaacaa	ccggggctgc	tgctttgact	ccaggatccc	tggagtgcct	180
tggtgtttca	agccctgca	ggaagcagaa	tgacacctct	ga		222

<210> 5

<211> 255

<212> DNA

<213> Homo sapien

<400> 5

atggccacca	tggagaacaa	ggtgatctgc	gccctgggtcc	tggtgtccat	gctggccctc	60
ggcaccctgg	ccgaggccca	gacagagacg	tgtacagtgg	ccccccgtga	aagacagaat	120
tgtgggtttc	ctgggtgtcac	gccctcccag	tgtgcaaata	agggctgctg	tttcgacgac	180
accgttcgtg	gggtcccctg	gtgcttctat	cctaatacca	tcgacgtccc	tccagaagag	240
gagtgtgaat	tttag					255

<210> 6

<211> 390

<212> DNA

<213> Homo sapien

<400> 6

atgggacggc	gagacgcccc	gctcctggca	gcgctcctcg	tcctggggct	atgtgccctg	60
gcggggagtg	agaaacctc	cccctgccag	tgctccaggc	tgagccccc	taacaggacg	120
aactgcggct	tccttggaat	caccagtgc	cagtgttttg	acaatggatg	ctgtttcgac	180
tccagtgtca	ctgggggtccc	ctgggtgttc	cacccctcc	caaagcaaga	gtcggatcag	240
tgcgtcatgg	aggtctcaga	ccgaagaaac	tgtggctacc	cgggcatcag	ccccgaggaa	300
tgccctctc	ggaagtgtg	cttctccaac	ttcatctttg	aagtgccctg	gtgcttcttc	360
ccgaagtctg	tggaagactg	ccattactaa				390

<210> 7

<211> 3280

<212> DNA

<213> Homo sapien

<400> 7

atgctggggc	tggctcctggc	cttgcctgtcc	tccagctctg	ctgaggagta	cgtgggcctg	60
tgtgagtact	gccctgactg	ccccggtggc	agggtgggcg	tgaagggaag	ggatccagga	120
taagggggga	ttctgcattc	atttaataat	ggccacctgt	cacatataca	ctttttcctg	180
cgctagccct	ttgaagtggg	tctttattgt	ccccatttca	cagacaagga	aaccgaggct	240
cagagaaagt	taacaactta	tccaaggcag	ccctgcccag	tctgtgttga	aatcagggtt	300
tgagcctgag	cccatccctt	atgaccccat	agccatcttt	gctggagatt	tctaaattac	360
aatataggtc	tttatgcatt	gttccacatt	tacaaagaaa	aaggaaagat	gcaggagaaa	420
aaccttgact	tcagaacact	gtcaataccg	gcaggcacia	ggttcattta	gccattgcat	480
agcaacctg	ccatgggggtg	tggctgctcc	attaacccaa	gtttgaagga	atgagggcat	540
ggcttttata	tgggtgtctt	ctgagcaggg	tcaaaggcag	tggttcccga	acttgcagcc	600
cattagaatc	acctggagag	ctttaaaaat	cctaatactt	ggggcacacc	agttacatca	660
gggcatctcc	aggcaagatc	caggcctcag	ctgttttgtt	ttgagatagc	cttgctttgt	720
cactcactgc	tggagtgcag	tggcacaaat	tcagctcact	gcaacctccg	cctcctgggt	780
tcaagcaatt	cttgtgcctc	ggcttcaagt	agctgggatt	acaggcatgc	cccaccatgc	840
ccagctaatt	ttttggattt	ttagtagaga	tggagtctcg	ctatgttggc	caagctgggtc	900
tcaaactcct	ggcctcaagt	gatcctcctg	ccttggcctc	ccaaagtgtc	ggaattacag	960
gtgtaagcca	ccatgcccag	ccaacgtcag	tcatttttaa	agctctgcag	ctgattccag	1020
tgtgagcgaa	gtttggatgc	caggaggata	agcaattacg	gactgggagc	aagagaaggg	1080
aatgtaagac	actgcacgtg	attgccattt	tcctaaggaa	atactcagtt	cgttaatgaa	1140
acgcagtga	cttctgctgc	acatacagac	atagaggctt	gcctgaaaca	tgaaaatatt	1200
ggggactgaa	ggatgtcccg	ggaggggtggg	acatgctcaa	caattcagga	aggggagatg	1260
cagaaaaaag	tgaaaagcag	gcagcatgcg	ttgcaatgat	ctctatggcg	tgtgcctctc	1320
ctgtcacggg	tttcatttaa	aacaaagggg	caaggttttg	ttgggtcaa	aatgaagggt	1380
aactttgttt	ctgggttcaa	gggaccccag	attccccagg	ggttcctgcc	agctggaagg	1440
taccaggtc	cgtatgtgac	ttcccagaga	gggtgataaga	gcgtgccaa	gagaaagaca	1500
cttaggcaaa	tggccagagt	ccccgagctg	agcatttaac	agactgcctc	tctttaaata	1560
ttcacaggga	aagtgcattt	tcctaagggc	gagggtttca	gcagtgggtg	aactcggcgg	1620
gggtggggcgg	agcgggagga	tgcaaaactg	caaagtgaag	caaacacact	caccgcagcc	1680
cagcaagggc	tctggcagct	gacagggtct	tgtctgggac	agctgcaaac	cagtgtgccc	1740
tggcagccaa	ggacagggtg	gactgcggct	acccccatgt	cacccccaa	gagtgcaaca	1800
accggggctg	ctgctttgac	tccaggatcc	ctggagtgcc	ttgggtgttc	aagcccctgc	1860
aggaagcagg	taaggcccca	gtggcatcgt	ggtctgggcc	cagccccata	aggcaggggg	1920
tctcagggcc	tccctgtcct	ttctgggctg	gagatggagg	cacaaggacc	ccaggaagcc	1980
acacacacac	acctgttcca	aggcctcaga	gcagaggctt	cacacttagg	gcagccatgg	2040
ccaggggtcg	tctctttctg	tcccctttat	gtaaaaacata	aaagcaattg	tttcaaaaag	2100
gtgttcaaaa	tgatggcatc	gcatagaggg	aactgattta	gtaactattc	ttgagagaag	2160
tggaaacgca	taggtgtgga	aagccgggcc	gacttttggg	ctgtttttgc	aaatcggccc	2220
cccagagtct	tgtcattttg	ggcatccctt	acacagacgg	caggcgggtc	cagccctaga	2280
cgtcaggcct	cgggtgccaca	ccccacctcc	cccactctgc	cccccaaca	ggtcactctc	2340
tctccctctc	tctgccgtgg	tggaggcag	gtgcaggcca	accacctggg	gggttccctc	2400
cccagggggc	gagagcctgc	gtgctgtgcg	ggtaacagat	ggccctgcac	acgggtttgc	2460
caccttggtc	ccaccaggct	tagctgcccc	acatcgtggg	tggggcgatt	ggctataagc	2520
catctgccat	gtccaagtgc	cagctcagcc	cccacgaagg	ccgcacctgc	gtgaggtacc	2580
ttcctggaac	cagcatccag	aggggcctct	cttgcccttt	gtcctagggt	gaaatgctgg	2640
aggctgagtc	ctgctggccc	cggctccctg	atcaatgatg	ggccctgccc	cagggcctcc	2700
cttcacctc	cccagcaagt	ccagggtagg	gggtgggggtg	gggggtccaga	gaaggccagg	2760
agagagaggg	gtctggctac	tgtccactgc	cggctcctgtt	ccttcagctc	cactggaact	2820
acactctcct	ctgagtgcc	gccatggccc	tgccaaaggcc	catctcgctt	gttatctgcc	2880
tgatccctgg	gtcccactat	cttgcttagc	aacccgaggt	gggaatcttg	gctattcccc	2940
catgtgggtg	ggactcaaca	ctccccggtg	actctgggga	ggaggcagca	ctaggtgctg	3000
gaccttgagc	ctgccctgac	cttggaagc	tgggcagcgt	gggtggagag	agactgtcca	3060
cacaagcctt	tgtctgtgtt	gcagaatgca	ccttctgagg	cacctccagc	tgcccccggc	3120
cgggggatgc	gaggctcgga	gcacccttgc	cggctgtga	ttgctgccag	gcactgttca	3180

tctcagcttt tctgtccctt tgctcccgcc aagcgcttct gctgaaagtt catatctgga 3240
gcctgatgtc ttaacgaata aaggccccat gctccaccgc 3280

<210> 8

<211> 4623

<212> DNA

<213> Homo sapien

<400> 8

dccctgggggt gcagctgagc tagacatggg acggcgagac gccagctcc tggcagcgct 60
cctcgctcctg gggctatgtg ccctggcggg gagtgaagaa ccctgtaagt gaaggagagg 120
gtcttttttat gtgctttctt tatttctctt aaagaaaaaa aaaaagcaca accataaatt 180
aacttgagag ggggaatggc tataaaggca tctggcaatg tgtgtgttc acatgggatt 240
tgccactgct caggaggggt gctccaagaa gggcctccct cctagggaaa ggctgagtga 300
cggcaggtgt cagcgggccc cgtgtcgggc caggagggca tccaccacaa gggtccttgg 360
agtcccagag cactcacctc tcgcctggat ctggcccttg ggtccatctg ttcacctcc 420
tctaggaggg ttttgttttt gtttttttcc gagacaggat ctggctttgc cgcccaggca 480
ggagtgcagt ggtgtgatct tggctcactg caacctctgc ctccaggct caagtgatcc 540
tcccacctca gccgctgag tagctgaaac cacagttgtg gaccatcatg cccggccaat 600
tttttttttt gtattgtttg tagagatggg gtttcgacat gttgccagg atggctctga 660
actcctgagc tcaagcaatc tgcccgcctc ggcttcctaa agtgcctggga ttataggat 720
gagccaccat gcctggcctt tttttttttt tcctttttaa ctaataataa aatttcagca 780
aagccctatc ggcttctcag gaggaacccg cattgcctaa atatgggcaa gataagactt 840
tgtgtttctc tatgtggcaa caagacagta gaggcattcc ctagaacctc tgagagaagg 900
agcagtgtgg tctggggtac cagggtgggg ccgactgagg gtctttccac agcccoctgc 960
cagtgcctca ggctgagccc ccataacagg acgaactcgc gcttccctgg aatcaccagt 1020
gaccagtgtt ttgacaatgg atgctgttcc gactccagtg tcaactgggt cccctgggtg 1080
ttccaccccc tcccaaagca aggtaatctt ccagggaatc ttctggggc agcagctggc 1140
aaccacggac ccagcttcac aggcggagcc cagagcaggg gccggaggag cccagttgc 1200
tagtctaggg ttagcctggg tgggttagtc tcgagctagc cccggttggg tagtctgggg 1260
ctagcccagg ttggttagtc tagagctagc ccaggttggg tagtctgggg ctagcccagg 1320
ttggttagtc tggggctagc ccaggttggg tagtctaggg ctagtgtagg ctagttagtc 1380
taaggctagc ccaggttggg tagtttggag ctagcgcagg ttggttagtc tggggctagt 1440
agccacgggt ggtagcctg gagctagccc aggttgggta gtctagggt agcgtaggct 1500
ggtagtctg gggctagccc aggttgggta gtctggagct agcccagggt ggtagtctg 1560
gggctagtag ccagggttg ttagtctggg gctagcccag gttgggttag ctagggctag 1620
tgtaggctag ttagtctagg gctagcccag gttagttagt ttggagctag cacagggtga 1680
ttagtctggg gctagtagcc taggttgggt agtctggagc tagcccaagt tggtagtct 1740
agggctagca taggctgggt agtctggggc tagtagccta ggttggtag tctggagcta 1800
gccagggttg gtagtctag ggctagcgta ggctgggttag tctagggcta gccagggttg 1860
gttaatcgga gctagcccag gttgggttag ctggagctag cccagggttg ttagtctgag 1920
gctagtagcc cagggttggt agtctggggc tagcccagg ttgttagtct ggagctagcc 1980
cagggtgttt agtctggagc tagcccagg ttggttagtct gggactagcc tggactgcta 2040
gtctagagg agcctagagg actgctagtc tagaggtag ctagggctag cccaggttgg 2100
ttagtctggg gctagcccat gttgggttag cttagactag cctggactgc tagtctagag 2160
gtagcccagg ttgtttagtc tggtagtagc ctggactgtt agtctagagg tagcccagg 2220
tggtaggtt ggtagtctg ggactagtct ggactgttag tctagaggta gccagggttg 2280
gttagtctgg gactagcctg gactgttagt cttagaggtag cccagatttg ttagtctggg 2340
actagtctgg actgctagtc tagaggtagc ccaggttggg tagcctggg ccagcctgga 2400
ctgttagtct agaggtaacc caggctagcc aacagtga gaataatttc ccacctaccc 2460
tgtttctaca ctgttagtct tttcaacaga catgtgtgtg tggagccatc agttttactt 2520
tagttgagaa aaaaatatat atatatatag taggtctcct ctagtttttg aagtgtgact 2580
tctgaagaag cttccatggg gaaatgaagg tatttaatag gacagcagta acataagggc 2640
tgacagccct caaatgttag ggaagggaag gaagccttct aggggtcttt gggagtga 2700
tttatgttag tgcacgggat caggaccacaa gttgtaacgc cgacgagtgc tcaaaggag 2760
gttgtgtgtg tgtcgtgcac ctgtgtgcgt ggaaccaggc acgtcctctg gagaaggagg 2820
attcatcccc aagattgttg ctgggaggct tgctggggcc cgcagggaac ccaggcagat 2880
ggtggattgt tcacgagcgc ccactgaatg gcagtgtctt tgggaatcaa taccatgtcc 2940

aaacgctttc	catctttacca	agggtgccac	aaaccttttc	tcattcttggc	ccggggggacc	3000
accccattta	ctgagaacac	tgagtcccga	gaggcaaaat	gattttcccca	aggcggggga	3060
ctccagagct	tctgactgtg	accaccccac	atggggcccca	ccttcgcgga	ggacaggcca	3120
gccaaagcgtc	gctggggccg	acactttccac	agtcccccg	ggaggcggtc	ccagggggccg	3180
acactttccac	agtccccggg	ggaggccgtc	ccgggggatg	ctgccccagg	cagcacctca	3240
tgatccacgg	aggctgcaaa	tcagcgctgc	tctcagagga	ggaagggggtg	gagctttcca	3300
gggcacagca	ggcctgactg	gggtctcggtg	ctgtgcctgt	cccatggcag	agtcggatca	3360
gtgcgtcatg	gaggtctcag	accgaagaaa	ctgtggctac	ccgggcatca	gccccgagga	3420
atgcgcctct	cggaagtgtc	gcttctccaa	cttcattcttt	gaagtgcctc	ggtgcttctt	3480
cccgaaagtct	gtggaaggta	acgtcgctgt	gggactctct	gtctgggtcc	cggacacccat	3540
gattcctcct	ccgtccgtag	agggtgggggtg	cagggaggggg	agctgcctcg	cagcctcagt	3600
gccatcgagc	ccaggggccc	tgcttcctat	gggattctga	aggcaattcc	agaatgttct	3660
tggaagac	agcgtctttt	caataagttt	atagcctcca	gcattgccac	tgctgcctct	3720
gtgatggctc	tagaaacagc	ggctcatccc	tggtgcctcc	ccagggtgtg	caacggttcag	3780
aggcgttgcc	tgttttattg	caagcccctc	tgcatcttga	ggctactgag	tgtcttgac	3840
tgtgctgggt	accagagagg	gcccactca	agcagacctg	gccccctctc	ccgtggcttc	3900
cccgttctcc	cccacatgac	cccgaatgac	aaacctcatc	cacaacgtcc	tgctccgggc	3960
agtcgccgga	gggtcccgcc	ggcagagggtg	aacgggtcca	cttctccac	ccgcttagtg	4020
atagtgtgtt	cctgactcgg	agtgtggcga	ggtaaaaaaa	gaccaagcag	atccaggaaa	4080
atggggaaag	agctactggc	ccttgaagga	tgcttttct	tttcttttg	ttaggatata	4140
aaagcactcc	aaagagcgaa	atatttcatg	ttcaggattt	tccgagtgat	tttttttatg	4200
tgacctaaag	gtccacctag	aaaatgttca	cttgtctggg	gagaatgcgc	cccacagagg	4260
aaactctggc	ctgggggtgg	aagatttggt	ccctttacac	ccctccccc	ggaaaggagc	4320
tccttcttca	gtaggaagct	cctgggcaaa	gtgatgcacg	cccacccag	cttcgcagcc	4380
taggcactcc	catttctggg	gttcccttac	caaccatctt	gcatttaaac	ttctagactg	4440
ccattactaa	gagaggctgg	ttccagagga	tgcatctggc	tcacggggtg	ttccgaaacc	4500
aaagaagaaa	cttcgcctta	tcagcttcat	acttcatgaa	atcctgggtt	ttcttaacca	4560
tctttctctc	attttcaatg	gtttaacata	taatttcttt	aaataaaacc	cttaaaatct	4620
gct						4623

<210> 9

<211> 4252

<212> DNA

<213> Homo sapien

<400> 9

atccctgact	cggggtcgcc	tttggagcag	agaggaggca	atggccacca	tggagaacaa	60
ggtgatctgc	gccctggctc	tggtgtccat	gctggccctc	ggcaccctgg	ccgaggccca	120
gacaggtaag	gcgtgcttct	tctgtctctg	tggggccaca	gccagctctg	gcagcctccg	180
ccaggagcca	ctgttttaca	tacatatttt	tgagcacctg	ttttgtgcca	ggtgctgttc	240
taggccctta	aaagtataat	caatttacag	gatcggcaaa	agcagggtga	gagtaactca	300
gggtggcagg	gcccccgagg	accttcgaga	agtgcgacga	ggagggggct	gcttccagtc	360
ggggctgttt	tcctgtgtta	ggaagactat	acaatcctcc	caagtgtcat	gtttcaaaga	420
ggaagtgttg	gcgtggggct	tcagaatagt	gcttttgact	gttcatgcca	acatctcccc	480
caggggcaga	ccctcccaag	gcccattccag	ataggcccaa	atgccgggtc	cagtgatggc	540
cacctgggag	accctctccc	acaggcccga	atgcccgtcc	cagtgggtgg	caactgggag	600
accctctcct	acagggttct	gggctccctc	gggatccatg	ctctgggagt	caaagccacc	660
tctctcatga	gtgcgtggct	ggcaacccat	attccctggt	gttgtcaagt	ggatcgggtg	720
ccctgggtcc	ttctagggag	tggaggagga	ggccattctt	gcttctcttg	gaagtgtttg	780
catctcaact	cctttacctg	cagaatggat	caacggctctg	ccctagggtc	gtcaggaaat	840
gctgtgtggc	agcatctcgc	acttgcactt	tgccagctgt	ggggagctga	ataacttatt	900
tgccgttatt	aggtacagtt	tcaagggtgg	ggcaggagaa	agggctttct	acgtttccaa	960
agcaagggtt	tccagagagg	cctgaagagg	gagcgcccag	tgggtgctgtc	cgtgccccca	1020
ctgccctcca	gccacctctt	gatctctgct	gtgggggtacc	gggcctgagg	ggtgggcttg	1080
ggcagcgtag	aagagcagcc	agcattgggc	tgacgtggga	agaccccca	gcccattggca	1140
gggagcgggg	gagctttgga	acccgagaga	ggaagtggcc	tcgggtgtaca	gaacgaactg	1200
ggtgggtccc	cgtgctggcc	acccccaggc	ccatctgcct	gcgcctttgc	ccccaccca	1260
gccccagct	ctgccccctg	tgctgtggga	tcacagaggc	cgtggcaaac	tccctcccc	1320

acccccacaca	ccctctgggt	caagggtcag	agcgtctttg	cgggtcactc	aggtccatga	1380
tcctgttaca	actgaaatct	agaaaattgt	gattacagtt	tagtgcatte	gtgtgtggaa	1440
accatttcca	tttatttcca	tcatgcgaca	aagacaaagc	gggtgggcaa	gacagagtct	1500
gccggaggca	gagcaccggg	gctggaaatc	ttcctccctg	aggaggaaac	cccccgacc	1560
cccaggatga	tgatcctccc	tcaccacggg	gcctctcttg	acccccacag	tgtcccgggg	1620
gtgggcgatg	atcaccttca	cgtcgcgatg	gatccagacc	ccaggagggc	aaggttccca	1680
tggaagctgc	tgggcagcgg	gagctgaaca	cggatccttc	ccagcaagcc	aggaacactt	1740
tctccaaaga	catctcgagg	cagtccttga	tagcaaaagca	gacaagagaa	cagccccctct	1800
cggcctcccc	tggggcgccc	tcacctgagc	cagtgtggcc	agactgagtt	cctccccctcc	1860
tatgccccaa	ggcaggggaca	gggaccggag	ggtgctctgg	gctcctcttt	cacccccctgc	1920
tgcaggctgt	caaccaccag	atcctaatag	gttgctttct	gagacctttg	attccgcgga	1980
gctcagagcc	tgaagctctg	gtgttagaac	ctcttgcata	agatcctgcg	gcagccccca	2040
gccagcccca	tctgtccacg	tgtcttcctc	ctctagatcc	ctttcctcac	tgccctgctt	2100
caagctgttt	cacagcttgt	accctctgtc	ggctcctcct	agaccacccc	acccgggtcct	2160
ctcaccttac	ctgcaatggg	tttccacctc	ctgaacacac	ctgggtctct	ggaatggcct	2220
ttgcccatgc	ggctccatct	tcacctgggt	aacctcctcc	tgcagggagc	ccccctgctt	2280
tgttcaacct	gcttgtcatt	ggcctctccg	gggagtgcct	tacccccgtg	gttacccctgg	2340
gcaccctggg	acgatggcct	tgcgttgtct	cgcacatgtt	cttgcccttc	tcctccatca	2400
gatccttaga	ctcttttttt	tttttttttg	agatggagtc	ttgctctgtc	actcaggctg	2460
gagtgcattg	gtgcgatctt	ggctcactac	aacctctgcc	tcctgggttc	aagtgattct	2520
cctgctcag	cctcccaagt	agctgggatt	acagacgtgt	gccacaatgc	ccgcctaatt	2580
ttttgtattt	ttagtagaga	tggggcttca	ccattttggt	caggctgggtc	ttgaactcct	2640
gacctcaagt	gattcacctc	cttcagcctc	ccaaagtgtc	gggattacag	gcattgagcct	2700
gggccccagat	atttagactc	ttattaatga	cttctctggt	tttaatttct	gggtctctct	2760
cacctggcac	agtgcctggc	ttttgccatg	ctagctccca	cttctcatgc	acacaaatgg	2820
tgctcagtaa	atatttatgt	attgagtaaa	atttaataat	cattttgttga	aattaaaaag	2880
tgaataaata	agttacctag	aaagatgcaa	agtccacaaa	cctggggcac	cttgcatttt	2940
ccctgagcgt	aatgtttgca	catcaggatg	tgaggaccac	gtctccctct	catgtcctga	3000
gggttttata	tccgcctcac	tggacagtgt	ctgatgtcat	tggagaagga	agctggatgg	3060
gtgtgtgcat	gataacatca	aggaattcag	cccacaactt	actttgcttc	ttacctgtgc	3120
actttcagag	acgtgtacag	tggccccccg	tgaagacacg	aattgtgggt	ttcctgggtg	3180
cacgccctcc	cagtgtgcaa	ataagggtct	ctgtttcgac	gacaccgctc	gtgggggtccc	3240
ctggtgcttc	tatcctaata	ccatcgacgt	ccctccagaa	ggtatggcct	ttttatacga	3300
tgggttctga	agatttagaa	ttagttagaa	aagtcattta	agactacaga	ggctctgac	3360
agcatcacca	gctatgcctt	tacacagagt	cacggccgcc	agtgggtggtg	caatggggta	3420
gcctgagtc	ggctgcattc	aggtccagga	atagaaaggc	agggttaagg	gacttgggaa	3480
gaaacctgat	ttccccccgg	cttctcttca	catctctaac	caaaagcctg	ggaagagcca	3540
ctgttggtaa	cgctttctag	cttgccctagg	atagaggggg	aaggcatgac	gaaatctgaa	3600
gacatttcat	gtattctttt	tttttttttt	tttttgaaat	ggagtctcgc	tccgttgccc	3660
ctgagctgga	gtgcaatggt	gcgatcttgg	ctcactgcaa	tctctgcctc	ctgagttcaa	3720
cctcagcttc	ctagtagctg	agattacagg	tgtgtgccac	tacgcccagc	taaatttttt	3780
ttgtattttt	agtatagacg	gggtttcacc	atgttggcca	gaccggctct	gaactcttga	3840
cctcaggtga	tctgccccgc	tcagcctccc	agagagctgg	gattacaggg	gtgagccacc	3900
gtgcccggct	gacagttcat	gtttttctaaa	gaatgtgcct	atggatactt	taaagtaaaa	3960
actctgtaat	tgttttaaatg	tgaagaaaaa	tgtttatcct	cactaaagca	tctctttctc	4020
cctccccctc	acccctgtag	aggagtgtga	attttagaca	cttctgcagg	gatctgcctg	4080
catcctgacg	cgggtgcctc	cccagcacgg	tgattagtcc	cagagctcgg	ctgccacctc	4140
caccggacac	ctcagacacg	cttctgcagc	tgtgcctcgg	ctcacaacac	agattgactg	4200
ctctgacttt	gactactcaa	aattggccta	aaaattaaaa	gagatcgata	tt	4252

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 38/16

US CL : 514/2, 12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 12; 435/69.1, 91, 172.3, 320.1, 235.1; 536/27, 23.5; 530/300; 935/9, 10, 23

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 6,221,840 B1 (PODOLSKY et al) 24 April 2001 (24.04.2001), abstract, column 1, lines 25-38, column 15, lines 33-47, column 16, lines 1-5, column 27 lines 14-35, column 28, lines 13-34.	1-6, 34-38, 42
X	US 6,063,755 A (PODOLSKY et al) 16 May 2000 (16.05.2000), abstract, column 1, lines 29-33, column 3, lines 61-67, column 9, lines 31-34, column 10, lines 1-3.	1-16, 34-38, 42
A	MODLIN et al. Trefoil Peptides: Mitogens, Motogens, or Mirages? J. Clin. Gastroenterol. 1997, Vol.25 (Suppl. 1), pages S94-S100.	1-7, 10-16

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 July 2002 (30.07.2002)

Date of mailing of the international search report

11 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

B. Dell Chism

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-55 (in-part)

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/12891

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

1. This International Preliminary Examining Authority has found greater than 1 invention claimed in the International Application covered by the claims indicated below:

This application contains more than one invention or group of inventions wherein the inventions or group of inventions consists of a method and a product:

Group I, claim(s) 1-55, drawn to methods of treatment by trefoil peptide and a second therapeutic and the composition for such treatment.

However, the first invention claims a method of treatment requiring a trefoil peptide and subsequently claims three peptides of similar function but are structurally different for use in the treatment scheme. One or more of the peptides is/are known in the art (i.e. intestinal trefoil factors) (U.S. Patent No. 6,063,755) and therefore lack a special technical feature. Applicant must elect one peptide of the three. Additionally, the first invention claims a second therapeutic for use in conjunction with one of the structurally different peptides, however, the applicant claims six different classes of compounds to represent the second therapeutic wherein the classes are further divided into subgroups of therapeutics. The applicant must elect one representative for the second therapeutic. Furthermore, the first invention claims formulations for the peptide and the second therapeutic as being the same or different. The applicant needs to elect one formulation as same or different one from the other. For explanation of possible combinations see below:

1. Trefoil peptides: [A] spasmolytic polypeptide; [B] pS2; [C] intestinal trefoil factor. Applicant will receive search for [A] or Applicant must pay additional for either or both [B] and [C].

2. Second Therapeutic: a. anti-inflammatory;
b. Antibacterial agent; (i) penicillin, (ii) cephalosporin, (iii) tetracycline, (iv) aminoglycoside, or (v) povidoneiodine.
c. anti-fungal agent; (i) nystatin or (ii) Amphotericin B.
d. anti-viral agent;
e. analgesic; (i) lidocaine or (ii) benzocaine.
f. steroid; (i) triamcinolone or (ii) hydrocortisone.

3. As to each of (a) to (f), Applicant needs to elect from (a); after first member of group additional fees for each member are required.

3. Formulation: a. same formulation
b. different formulation

As demonstrated by the itemization above, there are 78 possible combinations of methods. Additional fees are required for searches beyond the first member or each group above. If additional members are not chosen and the required fees paid for the additional members, the first member of each group only will be searched.

Continuation of B. FIELDS SEARCHED Item 3:

INTERNATIONAL SEARCH REPORT

PCT/US02/12891

STN, SCISEARCH, BIOSIS, WEST, MEDLINE, TREFOIL, INTESTINAL, PEPTIDE, FACTOR, INFLAMMATORY,
BACTERIAL, FUNGAL, ANTI, VIRAL, ANALGESIC, STEROID, LESION, ALIMENTARY, INFLAMMATION

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.